Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -7.76 is 154% below its 5-year average of 14.48, near the low end of its 5-year range (-7.76–49.94).
90.06% below its 12-month average of -4.08.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -3.70.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 17 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-09-16T00:05:27.732Z. Historical observations retain their original dates. Historical series through 2024-06-28.
EARNINGS PER SHARE (EPS)
-7.76
EARNINGS PER SHARE (EPS) AVG TTM
-4.08
EARNINGS PER SHARE (EPS) AVG 3Y
9.21
EARNINGS PER SHARE (EPS) AVG 5Y
14.48
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-90.06%
CURRENT VS 3Y AVG
-184.24%
CURRENT VS 5Y AVG
-153.60%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BioNTech SE
Market Cap
$24.29B
Earnings Per Share (EPS)
-7.76
TTM Avg
-4.08
3Y Avg
9.21
5Y Avg
14.48
Market Cap
$24.68B
Earnings Per Share (EPS)
7.85
TTM Avg
3.38
3Y Avg
2.74
5Y Avg
2.31
Market Cap
$25.68B
Earnings Per Share (EPS)
7.82
TTM Avg
6.79
3Y Avg
7.36
5Y Avg
7.17
Market Cap
$26.57B
Earnings Per Share (EPS)
12.09
TTM Avg
9.71
3Y Avg
9.57
5Y Avg
13.14
Market Cap
$26.88B
Earnings Per Share (EPS)
44.49
TTM Avg
41.42
3Y Avg
39.43
5Y Avg
36.04
Market Cap
$27.29B
Earnings Per Share (EPS)
9.42
TTM Avg
8.33
3Y Avg
8.09
5Y Avg
9.83
Market Cap
$21.24B
Earnings Per Share (EPS)
27.91
TTM Avg
28.29
3Y Avg
23.40
5Y Avg
19.31
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | $24.29B | -7.76 | -4.08 | 9.21 | 14.48 |
| Incyte Corporation (INCY)vs › | $24.68B | 7.85 | 3.38 | 2.74 | 2.31 |
| West Pharmaceutical Services, Inc. (WST)vs › | $25.68B | 7.82 | 6.79 | 7.36 | 7.17 |
| Labcorp Holdings Inc. (LH)vs › | $26.57B | 12.09 | 9.71 | 9.57 | 13.14 |
| Mettler-Toledo International Inc. (MTD)vs › | $26.88B | 44.49 | 41.42 | 39.43 | 36.04 |
| Medline Inc. (MDLN)vs › | $27.15B | 0.86 | 1.48 | 0.80 | 0.80 |
| Quest Diagnostics Incorporated (DGX)vs › | $27.29B | 9.42 | 8.33 | 8.09 | 9.83 |
| United Therapeutics Corporation (UTHR)vs › | $21.24B | 27.91 | 28.29 | 23.40 | 19.31 |
| STERIS plc (STE)vs › | $20.49B | 8.18 | 7.08 | 4.77 | 4.37 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $28.94B | 3.45 | 4.46 | 4.05 | 4.25 |
Trailing EPS (TTM)
$-7.76
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -5.30 |
| 2024-12-31 | -2.87 |
| 2023-12-31 | 4.27 |
| 2022-12-31 | 40.74 |
| 2021-12-31 | 49.94 |
| 2020-12-31 | 0.07 |
| 2019-12-31 | -0.95 |
| 2018-12-31 | -0.24 |
| 2017-12-31 | -0.46 |
